Malignity Markers in Canine And Feline Mammary Neoplasms
World Small Animal Veterinary Association World Congress Proceedings, 2004
Gal A., Cătoi C., Baba A.I., Iacob Sorina, Dombay E.
Faculty of Veterinary Medicine Cluj-Napoca, Romania

Often, mammary neoplasm malignity is subjectively appreciated by histopathology exams. Utilization of exact measurements techniques or malignancy markers is very important. AgNOR is a marker less studied in mammary neoplasms and has had very good results in appreciating malignancy in sarcomas such as the equine sarcoid and lymphomas (1, 2).

The material was represented by 10 cases (three cats and seven bitches), these presented mammary neoplasms. Cadavers and surgical samples represented the cases. After macroscopic exam samples were processed with the paraffin technique. Argentical impregnation was done using the Croker technique (2).

Results

Case 1: Stray cat, female, 5 years old, anaplastic solid carcinoma. AgNORs values: 3, 43% AgNOR/nucleu; 2, 65% AgNOR/nucleolus;1,29%.nucleols/nucleus. Case 2: Stray cat, female, 15 years old, simple tubular adenocarcinoma. AgNORs values: 1, 62% AgNOR/nucleus; 1, 61% AgNOR/nucleolus; 1, 02% nucleoli/nucleus. Case 3: Dog, female, Belgian shepherd, 8 years old; simple papilary adenocarcinoma. AgNORs values: 3, 36% AgNOR/nucleus; 2, 01% AgNOR/nucleolus; 1, 64% nucleoli/nucleus. Case 4: Dog, female, Caniche, 6 years old, mucous carcinoma. AgNORs values: 2, 55% AgNOR/nucleus; 2, 03% AgNOR/nucleolus; 1, 25% nucleoli/nucleus. Case 5: Stray dog, female, 9 years old, simple tubular adenocarcinoma. AgNORs values: 3, 31% AgNOR/nucleus; 1, 49% AgNOR/nucleolus; 2, 44% nucleoli/nucleus. Case 6: Dog, female, German shepherd, 6 years old, metaplastic carcinoma. AgNORs values: 3, 27% AgNOR/nucleus; 2, 10% AgNOR/nucleolus; 1, 54% nucleoli/nucleus. Case 7: Dog, female, Dalmatian, 8 years old, complex tubular adenocarcinoma. AgNORs values: 2, 46% AgNOR/nucleus; 1, 47% AgNOR/nucleolus; 1, 69% nucleoli/nucleus. Case 8: Dog, female, Caniche, 9 years old, simple tubular adenocarcinoma. AgNORs values: 1, 88% AgNOR/nucleus; 1, 63% AgNOR/nucleolus; 1, 17% nucleoli/nucleus. Case 9: Stray cat, female, 5 years old, simple tubular adenocarcinoma. AgNORs values: 2, 02% AgNOR/nucleus; 1, 97% AgNOR/nucleolus; 1, 03% nucleoli/nucleus. Case 10: Dog, female, Pit-bull, 5 years old, simple tubular adenocarcinoma. AgNORs values: 2, 71% AgNOR/nucleus; 1, 75% AgNOR/nucleolus; 1, 53% nucleoli/nucleus.

Conclusions

There are direct correlations between histopathology aspects regarding malignity and AgNORs marker. AgNOR/nucleus is directly proportional with AgNOR/nucleoli, nucleoli/nucleus. We established a hierarchy regarding the malignity. In bitches: high aggressively - (case 3); (case 5); (case 6); mean aggressively - (case 10); (case 4); (case 7); low aggressively - (case 8). In cats: high aggressively - (case 1); medium aggressively - (case 9); low aggressively - (case 2). The AgNOR technique could be used in the appreciation of the malignity of the mammary carcinoma in cats and dogs. AgNOR quantification could be more precise if its surface is measured with image analyzing techniques.

References

1.  Baba, A I, 2002, Comparative oncology, Ed. Academia Româna.

2.  Catoia C., ET. ALL, 2000, Rev.Rom.Oncol.Comp., 3, 185.

3.  Croker, J., 1987, J. Pathol., 151, 111 - 118.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Cătoi
Faculty of Veterinary Medicine Cluj-Napoca
Romania


MAIN : Abstracts : Mammary Neoplasms
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27